Pharmacogenetic of the Antihypertensive Response to the Angiotensin II Blockers in Monotherapy or Associated to Hydrochlorothiazide.
Phase of Trial: Phase IV
Latest Information Update: 24 Jul 2009
At a glance
- Drugs Hydrochlorothiazide; Losartan
- Indications Essential hypertension
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Merck & Co
- 24 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Sep 2008 Planned end date changed from 1 Apr 2009 to 1 Jun 2009 as reported by CT.gov
- 25 Sep 2008 Status changed from recruiting to active, no longer recruiting as reported by CT.gov